Table 1 Clinical characteristics at baseline parameters and of all subjects
From: Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia
Group | Control group (n = 28) | Fenofibrate group (n = 28) | P |
|---|---|---|---|
Sex (male/%) | 17/60.7 | 20/71.4 | 0.604 |
Age (year) | 56.03±12.32 | 54.64±10.09 | 0.593 |
Duration of diabetes (years) | 5.21±2.02 | 5.83±1.39 | 0.716 |
Hypertension (number/%) | 10/35.7 | 11/39.3 | 0.500 |
AECI/ARB (number/%) | 7/25.0 | 8/28.6 | 0.768 |
CCB (number/%) | 5/17.9 | 5/17.9 | 0.636 |
Metformin (number/%) | 15, 53.6 | 13, 46.4 | 0.601 |
α-Glucosidase inhibitors (number/%) | 20, 71.42 | 22, 78.6 | 0.546 |
Sulfonylureas (number/%) | 12, 42.9 | 11, 39.3 | 0.791 |
Glinides (number/%) | 10, 35.7 | 11, 39.3 | 0.787 |
Insulin (number/%) | 6, 21.4 | 8, 28.6 | 0.786 |
Insulin/Oral medications (%) | 22.2 | 28.6 | 0.372 |
Simvastatin (number/%) | 12/42.9 | 10/35.7 | 0.392 |
Atorvastatin (number/%) | 9/28.0 | 10/35.7 | 0.591 |
Rosuvastatin (number/%) | 3/10.7 | 2/7.1 | 0.500 |
pravastatin(number/%) | 4/14.3 | 6/21.4 | 0.364 |
SBP (mmHg) | 137.75±13.77 | 137.71±9.59 | 0.996 |
DBP (mmHg) | 75.00±5.60 | 76.29±7.87 | 0.782 |
BMI, kg/m2 | 27.28±3.99 | 28.32±4.36 | 0.429 |
FPG, mmol/L | 7.92±2.16 | 8.27±1.31 | 0.606 |
HbA1c, % | 7.62±0.87 | 7.48±0.86 | 0.480 |
TG, mmol/L | 2.97(2.13,3,31) | 3.04(2.21, 3.29) | 0.606 |
TC, mmol/L | 4.59±1.14 | 4.79±1.01 | 0.474 |
LDL-C, mmol/L | 2.47±0.90 | 2.55±0.94 | 0.670 |
HDL-C, mmol/L | 1.02±0.20 | 1.09±0.24 | 0.275 |
Scr, μmol/L | 69.56±15.43 | 65.46±20.98 | 0.349 |
UA, μmol/L | 388.44±126.99 | 372.46 ± 72.78 | 0.803 |
UACR, mg/g | 105.00(64.00, 165.00) | 129.00 (53.00, 226.25) | 0.095 |
eGFR ml/min/1.73m2 | 94.01 (80.95, 120.95) | 105.36 (99.68, 116.92) | 0.066 |
FINS, μIU/mL | 12.9 (6.75, 15.78) | 12.05 (8.35, 14.95) | 0.101 |
HOMA-IR | 4.50 (3.13, 5.95) | 4.27 (3.05, 5.35) | 0.105 |
HOMA-β | 42.04 (25.33,75.23) | 49.51 [35.85, 70.05] | 0.127 |